PMID- 10914726
OWN - NLM
STAT- MEDLINE
DCOM- 20001116
LR  - 20220408
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 6
IP  - 7
DP  - 2000 Jul
TI  - Human leukocyte antigen class I allelic and haplotype loss in squamous cell 
      carcinoma of the head and neck: clinical and immunogenetic consequences.
PG  - 2794-802
AB  - The expression of human leukocyte antigen (HLA) class I molecules on the cell 
      surface is necessary for the presentation of peptide antigens to cytotoxic CD8+ T 
      lymphocytes of the immune system. Down-regulation of HLA class I gene expression 
      has been implicated in tumorigenesis, including squamous cell carcinoma of the 
      head and neck (SCCHN). Loss of MHC class I antigens may be one mechanism by which 
      tumor cells escape immune detection. We performed prospective immunostaining of 
      26 primary SCCHN tumors and samples of normal mucosa harvested several 
      centimeters away from the primary tumor, using a large panel of antibodies 
      directed against allele-specific as well as monomorphic determinants of HLA class 
      I molecules. Loss of expression of HLA class I proteins in the tumor was found in 
      50% (13 of 26) of primary tumors and was highly correlated with HLA loss in the 
      corresponding normal mucosa (P < 0.0001). Further analysis demonstrated that the 
      loss of HLA class I expression in the tumor was significantly associated with 
      regional lymph node metastases (nodal stage; P = 0.0388), and that the number of 
      HLA class I alleles lost in the normal mucosa was associated with subsequent 
      development of a new primary aerodigestive tract cancer (P = 0.042). A patient 
      with two metachronous cancers available for analysis had no evidence of HLA loss 
      in the first tumor, demonstrated allelic loss in the second cancer, and 
      subsequently died of disease. These results suggest that the loss of expression 
      of HLA class I alleles may have prognostic implications.
FAU - Grandis, J R
AU  - Grandis JR
AD  - Department of Otolaryngology and Pharmacology, University of Pittsburgh, 
      Pennsylvania 15213, USA.
FAU - Falkner, D M
AU  - Falkner DM
FAU - Melhem, M F
AU  - Melhem MF
FAU - Gooding, W E
AU  - Gooding WE
FAU - Drenning, S D
AU  - Drenning SD
FAU - Morel, P A
AU  - Morel PA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Carcinoma, Squamous Cell/*genetics/immunology/pathology/therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - *Genes, MHC Class I
MH  - Haplotypes
MH  - Head and Neck Neoplasms/*genetics/immunology/pathology/therapy
MH  - Histocompatibility Antigens Class I/*analysis/genetics
MH  - Histocompatibility Testing
MH  - Humans
MH  - *Loss of Heterozygosity
MH  - Male
MH  - Middle Aged
MH  - Mucous Membrane/immunology/pathology
MH  - Neoplasm Staging
EDAT- 2000/07/29 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/07/29 11:00
PHST- 2000/07/29 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/07/29 11:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 2000 Jul;6(7):2794-802.